We help oncology laboratory pharma professionals enhance patient care
Oncology professionals
We ensure NGS testing is simple to organise with timely results provided in a timely way signposting you to treatment choices that will benefit your patients.
Laboratory professionals
Our solutions always ensure that NGS testing and its clinical interpretation is delivered in a timely way for the benefit of patients.
Pharma professionals
We can gather the information needed to precisely match patients to drugs, evidencing clinical efficacy, safety and patient benefit.
Years of trust, countless tests run, genes, and trials explored
Our mission
OncoDNA’s ultimate mission is to improve all patients’ health by empowering healthcare providers, biopharma companies and researchers to deliver the promise of precision medicine. In this relentless pursuit of better care, we have been building an ecosystem of partners involved along the entire value chain – from translational research and drug development to patient treatment, monitoring and reimbursement.
Every day, our dedicated efforts focus on enhancing patient
access to Precision Medicine
Festival Of Genomics January 2025
We help you navigate a complex genomics ecosytem OncoDNA understands the complexities of the personalized medicine ecosystem and leverages over 10 years of expertise in genomic profiling to guide laboratories and oncologists in their use...
In this episode, Pr. Daniela Cesselli (University of Udine) discusses the strategic needs that drove the adoption of a CGP panel and the reasons behind choosing the 𝗢𝗻𝗰𝗼𝗗𝗘𝗘𝗣® 𝗞𝗶𝘁 solution. Was it to ensure timely...
Webinar : Comprehensive Genomic Profiling: What’s the Business Case? Hear the experience of an existing OncoDEEP® Kit customer
Is Comprehensive Genomic Profiling right for your lab? Download the webinar replay: Comprehensive Genomic Profiling: What’s the Business Case? Hear the experience of an existing OncoDEEP® Kit customer Wednesday, December 11, 20244:00 PM CET By...
MGI and OncoDNA join forces to offer laboratories a streamlined NGS workflow for implementing Comprehensive Genomic Profiling (CGP) OncoDEEP® Kit in clinical practice
Gosselies – Belgium, October 29, 2024 MGI (MGI Tech Co., Ltd. or its subsidiaries, together referred to MGI), a company committed to building core tools and technologies that drive innovation in life science, today announced...
The NHS South East Genomic Medicine Service transitions to the OncoDEEP Kit a Solid Tumour Panel that can transform oncology patients’ lives as a result of timely comprehensive genomic testing.
The NHS South East Genomic Medicine Service serves approximately 15.4% of the population of England and seeks to improve patient outcomes through care pathway development enabling timely and equitable access to genomic testing and genomically...
Validation of the OncoDEEP® Kit comprehensive genomic panel on the MGI platform
Introduction : This study aims to compare tumour characterization using the OncoDEEP® Kit end-to-end solution with an MGI sequencer as an alternative to Illumina technology. The validation results demonstrate that the MGI platform, by generating...
OncoDNA to attend the 36th European Congress of Pathology (ECP) in Florence
OncoDNA is taking part in the 36th European Congress of Pathology (ECP), to be held from 7 to 11 September 2024 in Florence, Italy. This event brings together pathology experts from across Europe to discuss...
Analytical validation of HRD calculation performed with the OncoDEEP® Kit Comprehensive Genomic Panel
Introduction : HRD validation with OncoDEEP® Kit for ovarian cancer This poster highlights the results of a rigorous study conducted on 76 ovarian carcinoma samples from four Spanish hospitals. The OncoDEEP® kit stands out for...
Detection of Intraspecies Contamination as a Quality Control Tool in The OncoDEEP® Kit Comprehensive Genomic Panel
Introduction Next-Generation sequencing (NGS) emerged as a revolutionary technology in genomics research aiding precision medicine for almost two decades, but it has its challenges. One of which is the intraspecies contamination which could affect assay’s...
